secwatch.observer — SEC 8-K summary
======================================

Issuer:     Turn Therapeutics Inc. (TTRX)
CIK:        0002023016
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001213900-26-003153
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Turn Therapeutics provides pipeline update; GX-03 Phase 2 data expected H1 2026, appoints Martin Dewhurst to board
--------------------------------------------------------------------------------

- Phase 2 trial of GX-03 for moderate-severe atopic dermatitis on track; interim and topline data expected first half of 2026.
- Martin Dewhurst (30+ year McKinsey M&A veteran) appointed to Board of Directors.
- Vaccine pipeline expanded to include intranasal influenza candidate; in-vivo/vitro studies start Q1 2026.
- Commercial partnership with Medline expected to generate near-term revenue in 2026 in wound care.
- Strengthened balance sheet via share purchase agreement extends cash runway into late 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026003153/0001213900-26-003153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026003153/ea0272490-8k_turn.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-003153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer